784 related articles for article (PubMed ID: 30891677)
1. TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma.
Alvarez MA; Freitas JP; Mazher Hussain S; Glazer ES
J Gastrointest Cancer; 2019 Jun; 50(2):207-213. PubMed ID: 30891677
[TBL] [Abstract][Full Text] [Related]
2. Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
Hussain SM; Kansal RG; Alvarez MA; Hollingsworth TJ; Elahi A; Miranda-Carboni G; Hendrick LE; Pingili AK; Albritton LM; Dickson PV; Deneve JL; Yakoub D; Hayes DN; Kurosu M; Shibata D; Makowski L; Glazer ES
Cell Oncol (Dordr); 2021 Jun; 44(3):673-687. PubMed ID: 33694102
[TBL] [Abstract][Full Text] [Related]
3. Stem cell marker nestin is critical for TGF-β1-mediated tumor progression in pancreatic cancer.
Su HT; Weng CC; Hsiao PJ; Chen LH; Kuo TL; Chen YW; Kuo KK; Cheng KH
Mol Cancer Res; 2013 Jul; 11(7):768-79. PubMed ID: 23552743
[TBL] [Abstract][Full Text] [Related]
4. Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas.
Neuzillet C; de Gramont A; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E
Oncotarget; 2014 Jan; 5(1):78-94. PubMed ID: 24393789
[TBL] [Abstract][Full Text] [Related]
5. Role of BCL9L in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer.
Sannino G; Armbruster N; Bodenhöfer M; Haerle U; Behrens D; Buchholz M; Rothbauer U; Sipos B; Schmees C
Oncotarget; 2016 Nov; 7(45):73725-73738. PubMed ID: 27713160
[TBL] [Abstract][Full Text] [Related]
6. Sauchinone inhibits hypoxia-induced epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma cells through the Wnt/β-catenin pathway.
Qiao Y; Yan LJ; Yan C
Anticancer Drugs; 2020 Oct; 31(9):918-924. PubMed ID: 32889895
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated macrophages promote pancreatic ductal adenocarcinoma progression by inducing epithelial-to-mesenchymal transition.
Xiong C; Zhu Y; Xue M; Jiang Y; Zhong Y; Jiang L; Shi M; Chen H
Aging (Albany NY); 2021 Jan; 13(3):3386-3404. PubMed ID: 33428605
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action.
Bartscht T; Rosien B; Rades D; Kaufmann R; Biersack H; Lehnert H; Gieseler F; Ungefroren H
Mol Cancer; 2015 Nov; 14():199. PubMed ID: 26588899
[TBL] [Abstract][Full Text] [Related]
9. TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma.
Thakur AK; Nigri J; Lac S; Leca J; Bressy C; Berthezene P; Bartholin L; Chan P; Calvo E; Iovanna JL; Vasseur S; Guillaumond F; Tomasini R
Cell Death Differ; 2016 Aug; 23(8):1358-70. PubMed ID: 26943320
[TBL] [Abstract][Full Text] [Related]
10. Kindlin-2 induced by TGF-β signaling promotes pancreatic ductal adenocarcinoma progression through downregulation of transcriptional factor HOXB9.
Zhan J; Song J; Wang P; Chi X; Wang Y; Guo Y; Fang W; Zhang H
Cancer Lett; 2015 May; 361(1):75-85. PubMed ID: 25724625
[TBL] [Abstract][Full Text] [Related]
11. Par-4 mediated Smad4 induction in PDAC cells restores canonical TGF-β/ Smad4 axis driving the cells towards lethal EMT.
Mohd Faheem M; Rasool RU; Ahmad SM; Jamwal VL; Chakraborty S; Katoch A; Gandhi SG; Bhagat M; Goswami A
Eur J Cell Biol; 2020 May; 99(4):151076. PubMed ID: 32439219
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor.
Yang HH; Liu JW; Lee JH; Harn HJ; Chiou TW
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360896
[TBL] [Abstract][Full Text] [Related]
13. A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.
Sempere LF; Gunn JR; Korc M
Cancer Biol Ther; 2011 Aug; 12(3):198-207. PubMed ID: 21613822
[TBL] [Abstract][Full Text] [Related]
14. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-mesenchymal transition via transforming growth factor beta in pancreatic cancer is potentiated by the inflammatory glycoprotein leucine-rich alpha-2 glycoprotein.
Otsuru T; Kobayashi S; Wada H; Takahashi T; Gotoh K; Iwagami Y; Yamada D; Noda T; Asaoka T; Serada S; Fujimoto M; Eguchi H; Mori M; Doki Y; Naka T
Cancer Sci; 2019 Mar; 110(3):985-996. PubMed ID: 30575211
[TBL] [Abstract][Full Text] [Related]
16. SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma.
Dardare J; Witz A; Merlin JL; Gilson P; Harlé A
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429474
[TBL] [Abstract][Full Text] [Related]
17. TGF-β Signal Transduction in Pancreatic Carcinoma Cells is Sensitive to Inhibition by the Src Tyrosine Kinase Inhibitor AZM475271.
Bartscht T; Rosien B; Rades D; Kaufmann R; Biersack H; Lehnert H; Ungefroren H
Anticancer Agents Med Chem; 2017; 17(7):966-972. PubMed ID: 27671303
[TBL] [Abstract][Full Text] [Related]
18. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
19. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.
Jiang H; Liu X; Knolhoff BL; Hegde S; Lee KB; Jiang H; Fields RC; Pachter JA; Lim KH; DeNardo DG
Gut; 2020 Jan; 69(1):122-132. PubMed ID: 31076405
[TBL] [Abstract][Full Text] [Related]
20. Differential roles of Src in transforming growth factor-ß regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Int J Oncol; 2011 Mar; 38(3):797-805. PubMed ID: 21225226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
